A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matchedsibling donor. The patient's pre-and post transplant course were complicated by an autoimmune disorder and her post transplant course was complicated by severe hepatic and gastrointestinal GVHD. A technetium-99m sulfur colloid scan 4 months post transplant and bone marrow studies 8 months post transplant demonstrated intramedullary hematopoiesis, complete resolution of marrow fibrosis, and partial resolution of osteosclerosis.
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A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matchedsibling donor. The patient's pre-and post transplant course were complicated by an autoimmune disorder and her post transplant course was complicated by severe hepatic and gastrointestinal GVHD. A technetium-99m sulfur colloid scan 4 months post transplant and bone marrow studies 8 months post transplant demonstrated intramedullary hematopoiesis, complete resolution of marrow fibrosis, and partial resolution of osteosclerosis. Bone Marrow Transplantation (2003) 32, 581-585. doi:10.1038/sj.bmt.1704172 Keywords: myelofibrosis; allogeneic stem cell transplantation; technetium sulfur colloid scan Myelofibrosis with myeloid metaplasia (MMM) is an umbrella term used to describe chronic myeloproliferative diseases in which a clonal stem cell disorder leads to ineffective erythropoiesis, dysplastic megakaryocyte hyperplasia, increased blasts, and a reactive myelofibrosis with consequent extramedullary hematopoiesis.
1,2 MMM includes agnogenic myeloid metaplasia (AMM, also known as idiopathic myelofibrosis) as well as the progressively fibrotic phases of essential thrombocytosis and polycythemia vera. 1, 3 Of all of the chronic myeloproliferative disorders, AMM is associated with the worst prognosis: a median overall survival of no more than 5.5 years. 2, 4 Patients with poor prognostic factors, including anemia, leukopenia, leukocytosis, circulating blasts, karyotype abnormalities, or hypercatabolic symptoms, have a median survival of less than 3 years with current conventional therapy. 1, 4 Multiple therapies have been attempted for palliation and, in rare cases, for cure, including multiple chemotherapeutic agents, androgens, corticosteroids, splenectomy and splenic irradiation, antifibrotic therapy, antiangiogenic therapy, and allogeneic and autologous hematopoietic stem cell transplantation (HSCT).
Case report
A 28-year-old female was diagnosed with myelofibrosis with splenomegaly in 1988. No therapy other than observation was instituted until a few years later when she began low-dose prednisone for thrombocytopenia. A bone marrow biopsy performed 10 years after her initial diagnosis demonstrated megakaryocytic hyperplasia and approximately 80% myelofibrosis, but her disease remained asymptomatic until 12-13 years after the initial diagnosis when she began to exhibit hypercatabolic symptoms, including persistent fevers, night sweats, and weight loss.
Within a few months of the onset of these symptoms, in mid-2001, she noticed symptoms attributable to extramedullary hematopoiesis, including weakness and malaise, easy bruising, and abdominal pain. An abdominal ultrasound in September 2001 demonstrated hepatosplenomegaly without evidence of portal vein thrombosis and a liver biopsy demonstrated extramedullary hematopoiesis replacing 25% of the liver mass, with frequent megakaryocytes. A bone marrow biopsy in October 2001 demonstrated less than 10% cellularity, no leukemic cells, prominent osteosclerosis, and approximately 90% fibrosis (Figure 1 ). At this same time, the patient received her first of many PRBC transfusions for an Hgb of 7.4 g/dl and she developed a fever. She was then referred to an oncologist in the bone marrow transplant program at UCSD where she began therapy in late 2001.
The patient began with FLAG chemotherapy (Fludarabine, Ara-C, and G-CSF) to eradicate possible leukemic transformation and decrease her organomegaly. She received only one dose of G-CSF, which was associated with severe left upper quadrant pain and was consequently discontinued; she overcame her cytopenias on approximately day +19. By late January, her hepatosplenomegaly had decreased by approximately 50% and her leukocyte count, at 5.0, was at its most normal for years, possible evidence of FLAG suppression of a preleukemic M7 clone.
On February , given on days 0, +2, and +5) for GVHD prophylaxis. She also received tacrolimus (0.03 mg/kg/day, dose-adjusted to achieve the target level of 10-20 mg/ml) for GVHD prophylaxis; and she was discharged on tacrolimus at the intended levels. Her leukocyte count nadir occurred on day +9 and she received G-CSF from day +5 through day +13, when her ANC rose to above 500.
On day 36 following her HSCT, the patient developed a lower extremity rash that appeared consistent with erythema nodosum and an immune workup was completed. ANA, dsDNA, RF, and ESR did not reveal autoimmune disease, but increasing her prednisone dose led to resolution of the rash.
Chimerism studies completed in early May 2002, 2 months post transplant, demonstrated 100% donor chimerism in myeloid and lymphoid lines. Her liver and spleen remained approximately 5 and 4 cm below the costal margin, respectively; but two attempts at post transplant bone marrow aspiration and biopsy were hampered by remaining, severe marrow fibrosis.
In lieu of these more standard bone marrow studies, a sulfur colloid nuclear medicine scan was performed to characterize the location of the engrafted donor cells. Reticulo-endothelial cells take up the technetium-labeled colloid and areas of active hematopoiesis light up on the film. On June 4, 2002, the patient received 15.7 mCi of 99m Tc sulfur colloid. Her scan is seen in Figure 2 and it demonstrated markedly greater marrow uptake than would be expected in a patient of her age, proving that she had intramedullary hematopoiesis, most notably in her skull and epiphyses.
In early June, the patient reported feeling well, in spite of the fact that she still required PRBCs three or more times a month. Then, in mid-June, 4 months post transplant, she developed severe gastrointestinal symptoms. Her prednisone and tacrolimus were increased for presumed chronic GVHD, which was soon confirmed by skin and rectosigmoid biopsies. Her tacrolimus levels remained subtherapeutic and her symptoms progressed. On June 17, 2002 (117 days post-HSCT), the patient was admitted for 2 1 2 months of supportive care, during which she developed pancytopenia, Citrobacter freundii septicemia, and severe hepatic GVHD (evidenced by ascites and icterus; total bilirubin to 28.6; direct bilirubin to 19.9; AST 67; ALT 183; alkaline phosphatase 280; CMV(À)). Gastrointestinal GVHD was manifested by chronic nausea, emesis, and steroid-refractory diarrhea, which improved somewhat with antithymocyte globulin (30 mg/kg/day Â 4 days) and infliximab (10 mg/kg/week). In late July the patients' condition began to improve with supportive care, and in late August she was discharged feeling much better.
After her discharge, she continued taking three immunosuppressants (prednisone 30 mg/day, mycophenolate 1 g b.i.d., and tacrolimus two tabs b.i.d.) and exhibited a persistent dependence on 1-2 U PRBCS/week to maintain an Hgb 48 g/dl. An abdominal ultrasound performed in early October demonstrated resolving hepatosplenomegaly, and a peripheral blood smear on October 25, 2002 revealed a normocytic, normochromic anemia with anisopoikilocytosis, polychromasia, and basophilic stippling with no teardrops seen. A bone marrow biopsy obtained on the same date showed impressive hypercellular marrow (80% cellularity), trilineage hematopoiesis with a left-shift in the myeloid line, normal megakaryocytes, relative erythroid hyperplasia, and only a slight, nonspecific 2+/4 increase in reticulin fibers with no evidence of trichrome-positive fibers or increased blasts (Figure 3 ). Marked decrease in the degree of osteosclerosis was also noted. In early November, she began 40 000 U of EPO/week for her anemia and began slowly weaning her immunosuppressants with close monitoring for any evidence of GVHD exacerbation.
Discussion
As in many cases of myelofibrosis with myeloid metaplasia, the etiology of our patient's disease is unclear. There may be an immune component to her disease, as evidenced by her presentation at a young age with steroid-dependent thrombocytopenia, the increasingly transfusion-dependent anemia later in her disease course and post transplant, and her erythema nodosum. However, of the few reported cases of autoimmune myelofibrosis in the literature, all are associated with a positive ANA, which our patient did not have. 5, 6 Furthermore, although the patient's later course might suggest an autoimmune hemolytic anemia, her IgGbased direct antiglobulin test was negative. However, her LDH was slightly elevated and a complement-based DAT was weakly positive. This could indicate an immune hemolytic anemia with minimal laboratory findings.
The patient's therapy was chosen in the light of the evidence that HSCT currently offers the most promise of cure for myelofibrosis with myeloid metaplasia. In one pilot study of autologous HSCT, 27 patients underwent PBSC mobilization with G-CSF alone or with G-CSF plus anthracycline-cytarabine induction and 21 of these went on to receive conditioning with oral busulfan (16 mg/kg) before autologous HSCT. The 2-year actuarial survival was 61%. 3 A joint European-American study of allogeneic HSCT with myeloablative conditioning was also promising. In this retrospective study, an initial cohort of 55 patients with a median age of 42 years received allogeneic BMT from HLA-matched related siblings (49 patients) or from alternative donors (six patients). The 5-year probability of survival was 54% for those receiving unmanipulated, HLAmatched related HSCT. The 5-year probability of treatment failure in these patients was 28%, and factors associated with higher risk of treatment failure included recipient age at transplant, presence of cytogenetic abnormality, and absence of grade II-IV GVHD. Furthermore, osteomyelosclerosis and Hgb r10 g/dl at the time of transplant were independent predictors for decreased survival. 4 Our patient clearly had a mixed prognosis: she had osteomyelosclerois and severe anemia at the time of her transplant, as well as prominent hepatosplenomegaly; however, her transplant was an unmanipulated matched related HSCT, she was young, and she survived severe GVHD.
As in the joint European-American study, HSCT is frequently used in combination with pre-transplant chemotherapeutic myeloablation, presumably to attain sufficient immunosuppression of the host, to prevent acute rejection of the allogeneic graft and to attain chemotherapeutic levels expected to completely eradicate the tumor load. However, there is increasing evidence that particularly in the context of allogeneic HSCT, nonmyeloablative conditioning such as our patient received (colloquially referred to as a ''miniallogeneic transplant'') may allow sufficient engraftment, relying on a graft-versus-tumor effect of donor T lymphocytes, while avoiding some of the toxicity, including prolonged cytopenia, of ablative therapy. 2, [7] [8] [9] In addition to pretransplant nonmyeloablative chemotherapy, our patient received her transplant with the added advantage of a course of FLAG chemotherapy approximately 1 month before her PBSC infusion. This reduced her organomegaly while suppressing possible leukemic transformation, providing essentially a 'chemotherapeutic partial splenectomy'. Admittedly, the role of splenectomy in response to organomegaly in patients with MMM is controversial, and no large, prospective randomized trials are yet available to inform the conversation. The debate is formulated around evidence from small, retrospective studies suggesting that while splenectomy appears to allow faster post transplant cell count recovery and alleviate symptoms associated with splenomegaly, it does not appear to alter post transplant mortality or 5-year overall survival. Furthermore, it may be associated with an increased risk of blast transformation, particularly in patients with pretransplant thrombocytopenia, and with an operative mortality of approximately 10%. 1, 10, 11 However, we hypothesize that end-stage myelofibrosis requires pretransplant chemotherapy to reduce organomegaly. This chemotherapeutic partial splenectomy provides the benefits of reducing splenomegaly, including symptomatic relief and reduction of a potentially significant 'sink' for the transplanted cells, while avoiding the risks inherent in an operative procedure that leaves only the liver and other less common sites for any extramedullary hematopoiesis while the marrow fibrosis resolves post transplant. Our patient's mass-related symptoms improved and her post transplant cell counts recovered in the same time frame reported for splenectomized patients in retrospective studies by Li and Deeg 11 and Tefferi et al.
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The patient's stable, post transplant decreased organomegaly implied that she had intramedullary hematopoiesis, but bone marrow aspirates and cores to prove this were difficult in the light of the extensive myelofibrosis and osteosclerosis that remained immediately post transplant. The UCSD nuclear medicine division proposed that a technetium-99m sulfur colloid scan might provide evidence of the distribution of her hematopoiesis, since the reticuloendothelial elements of the patient's bone marrow -as well as her liver and spleen -would take up the technetium-labeled colloid. The 99m Tc sulfur colloid scan has been used in a variety of clinical settings to demonstrate bone marrow elements, with the normal distribution of radiocolloid approximately 80% within the liver, 15% within the spleen, and 5% within the bone marrow. [12] [13] [14] [15] In our patient, the radionuclide scan provided encouraging evidence that no further medical management was needed in the light of her appropriate, intramedullary hematopoiesis, and it revealed this information in a relatively painless way for the patient.
At 8 months after the transplant, we were able to obtain a bone marrow biopsy and aspirate and they confirmed the scan's findings of intramedullary engraftment of her transplant and demonstrated impressive, complete resolution of her myelofibrosis and partial resolution of osteosclerosis. The novel diagnostic and therapeutic approaches taken in this patient were successful and although we continue to address the patient's transfusion dependence and her recent GVHD and consequent considerable immunosuppression, she is currently well, at home with her family.
